Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Sales reflect continued strong growth in oncology and vaccines
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Subscribe To Our Newsletter & Stay Updated
